Where is ViAqua located?

ViAqua is headquartered in Rehovot, Israel.

Who is the current CEO of ViAqua?

Shai Ufaz of ViAqua. They have also founded 1 company.

How many employees does ViAqua have?

As of Aug 31, 2026, the latest employee count at ViAqua is 14.

Is ViAqua a funded company?

ViAqua is a funded company, having raised a total of $12.6M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round.

When was the latest funding round of ViAqua?

ViAqua's latest funding was a $***** Series A round on Sep 05, 2023, with participation from 4 investors. Its primary sector is Nanotechnology. Globally, the Nanotechnology sector has seen $1.23B in funding in 2026 to date.

Where does ViAqua rank among its competitors?

ViAqua ranks 13th amongst 190 active competitors, of which 59 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was ViaNautis, which secured an undisclosed amount in Sep, 2026.

Who are the top competitors of ViAqua?

ViAqua's top competitors include Sirnaomics, Avadel Pharmaceuticals and Splice Bio. Among them, ViaNautis secured the most recent funding round in September, 2026.

ViAqua - 2026 Company Profile, Team, Funding & Competitors

ViAqua is a series A company based in Rehovot (Israel), founded in 2014 by Shai Ufaz and Shai Einbinder. It operates as a Developer of RNA-i formulated drug delivery technology for aquaculture. ViAqua has raised $12.6M in funding from S2G Investments and Nutreco. The company has 190 active competitors, including 59 funded and 15 that have exited. Its top competitors include companies like Sirnaomics, Avadel Pharmaceuticals and Splice Bio.

Company Details

Developer of RNA-i formulated drug delivery technology for aquaculture. The company has developed orally administered treatment in aquaculture to stop diseases from developing and to prevent viral epidemics. Its drug delivery platform uses proprietary RNAi nanoparticle formulation which is delivered via feed or immersion to produce and triggers a cell reaction to disable the viral infection.

Website: www.viaqua-t.com/
Email ID: *****@viaqua-t.com
Phone Number: +972 **********

Key Metrics

Founded Year

2014

Location

Rehovot, Israel

Stage

Series A

Total Funding

$12.6M in 6 rounds

Latest Funding Round

Series A, Sep 05, 2023, $*****

Investors

S2G Investments & 8 more

Ranked

13^th among 190 active competitors

Employee Count

14 as on Aug 31, 2026

Similar Companies

Sirnaomics & 219 more

View ViAqua's full profile

ViAqua has raised a total funding of $12.6M over 6 rounds. Its latest funding round was a Series A round on Sep 05, 2023 for $*****. 4 investors participated in its latest round. ViAqua has 9 institutional investors.

Here is the list of recent funding rounds of ViAqua:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 05, 2023	6261914	Series A	2226300	2419036	8111394	3146934
Jun 09, 2021	7074577	Series A	6598753	9120066	5305226	Thai Union Group & 6 more
Dec 13, 2018	4023830	Series A	2363715	7304508	4587454	Clay Capital

Access funding benchmarks and valuations. Sign up today!

View details of ViAqua's funding rounds and investors

The founders of ViAqua are Shai Ufaz and Shai Einbinder. Shai Ufaz is the CEO of ViAqua.

Here are the details of ViAqua's key team members:

Shai Ufaz: Co-Founder & CEO of ViAqua.
Shai Einbinder: Co-Founder of ViAqua.

View details of ViAqua's Founder profiles and Board Members

ViAqua's employee count trend

ViAqua has 14 employees as of Aug 26. Here is ViAqua's employee count trend over the years:

Uncover ViAqua's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ViAqua include Sirnaomics, Avadel Pharmaceuticals and Splice Bio. Here is the list of Top 10 competitors of ViAqua, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Walvax & 16 others	62/100
2nd	Avadel Pharmaceuticals 1990, Dublin (Ireland), Acquired	Pharma company with proprietary drug delivery tools and drug for narcolepsy	-	Venrock, RTW Investments & 4 others	61/100
3rd	Splice Bio 2020, Barcelona (Spain), Series B	Provider of a proprietary platform for gene therapy	$192M	Ysios Capital, EQT & 9 others	57/100
4th	Arcturus Therapeutics 2013, San Diego (United States), Public	Developer of RNAi technologies for the treatment of rare orphan diseases	$1.3M	Cystic Fibrosis Foundation, JLABS & 1 others	56/100
5th	NanoViricides 2005, West Haven (United States), Public	Targeted antiviral therapeutics	-	-	54/100
6th	ViaNautis 2018, Cambridge (United Kingdom), Series A	Developer of targeted nanomedicines for drug delivery	$25M	4Bio Capital, Origin Capital & 8 others	54/100
7th	RS Research 2015, Pendik (Turkey), Series A	Developer of smart nanomedicines and targeted oncology therapies using polymer-drug conjugate platforms	$14.1M	ACT, Istanbul Portfolio & 3 others	53/100
8th	Midatech 2000, Abingdon (United Kingdom), Public	Provider of novel drug delivery technologies for the treatment of diseases	$16M	JDRF, Leonne International & 4 others	53/100
9th	Entos Pharmaceuticals 2016, Edmonton (Canada), Series A	Provider of nanotech-based drug delivery solutions	$1.1M	Tao Capital Partners, State of California ... & 3 others	52/100
10th	InnoMedica 2000, Bern (Switzerland), Acquired	Developer of therapeutics to treat cancer	$10.3M	-	51/100
13th	ViAqua 2014, Rehovot (Israel), Series A	Developer of RNA-i formulated drug delivery technology for aquaculture	$12.6M	Nutreco, S2G Investments & 7 others	47/100